Apellis Pharmaceuticals, Inc. (APLS)

NMS – Real Time Price. Currency in USD

41.06

+0.04 (0.10%)

At close: May 12, 2026, 4:00 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

781M

397M

75M

Cost of goods sold

-102M

-118M

-60M

-7M

Gross Profit

902M

664M

336M

68M

Operating expenses (excl. COGS)

-846M

-829M

-853M

-663M

Operating Income

55M

-165M

-517M

-595M

Non-operating income, total

-31M

-32M

-9M

-57M

Pretax income

24M

-197M

-526M

-652M

Equity in earnings

Taxes

-2M

-1M

-2M

-669K

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

22M

-198M

-529M

-652M

Apellis Pharmaceuticals, Inc. (APLS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Apellis Pharmaceuticals, Inc. (APLS)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Apellis Pharmaceuticals, Inc. (APLS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Apellis Pharmaceuticals, Inc. (APLS)

Income Statement (Annual)

Income Statement (Annual)